Valerie Speirs

Summary

Affiliation: University of Leeds
Country: UK

Publications

  1. pmc Problems (and solutions) in the study of male breast cancer
    Valerie Speirs
    Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James s University Hospital, Leeds UK
    Rare Tumors 2:e28. 2010
  2. pmc Phyto-oestrogens and breast cancer chemoprevention
    Jane L Limer
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Leeds, UK
    Breast Cancer Res 6:119-27. 2004
  3. pmc Breast cancer cell lines: friend or foe?
    Sarah E Burdall
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    Breast Cancer Res 5:89-95. 2003
  4. pmc Oestrogen receptor beta: how should we measure this?
    V Speirs
    Br J Cancer 87:687; author reply 688-9. 2002
  5. pmc Male breast carcinoma: increased awareness needed
    Jonathan White
    Department of Surgery, Leeds General Infi rmary, Great George Street, Leeds LS1 3EX, UK
    Breast Cancer Res 13:219. 2011
  6. pmc British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
    Alicia T Parkes
    Molecular Medicine Unit, University of Leeds, UK
    Breast Cancer Res 4:202-4. 2002
  7. ncbi request reprint Hormone receptors in defining breast cancer prognosis--time for a rethink?
    Valerie Speirs
    Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James s University Hospital, Beckett Street, Leeds LS9 7TK, UK
    Nat Clin Pract Oncol 4:204-5. 2007
  8. ncbi request reprint Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients
    V Speirs
    Department of Medicine, University of Hull, England, United Kingdom
    Cancer Res 59:5421-4. 1999
  9. ncbi request reprint Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland
    V Speirs
    Medical Research Laboratory, University of Hull, United Kingdom
    J Clin Endocrinol Metab 85:1601-5. 2000
  10. ncbi request reprint Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?
    Valerie Speirs
    Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James s University Hospital, Leeds LS9 7TF, UK
    J Pathol 197:143-7. 2002

Collaborators

Detail Information

Publications65

  1. pmc Problems (and solutions) in the study of male breast cancer
    Valerie Speirs
    Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James s University Hospital, Leeds UK
    Rare Tumors 2:e28. 2010
    ..Here we describe our experience in establishing a large collection of male breast cancers in tissue microarray format suitable for biomarker analysis by immunohistochemistry...
  2. pmc Phyto-oestrogens and breast cancer chemoprevention
    Jane L Limer
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Leeds, UK
    Breast Cancer Res 6:119-27. 2004
    ..Despite the present ambiguity, current data do suggest a potential benefit from use of phyto-oestrogens in breast cancer chemoprevention and therapy. These aspects are discussed...
  3. pmc Breast cancer cell lines: friend or foe?
    Sarah E Burdall
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    Breast Cancer Res 5:89-95. 2003
    ..An alternative is to use cultures established from primary breast tumours. Here, we discuss the pros and cons of using both of these models in translational breast cancer research...
  4. pmc Oestrogen receptor beta: how should we measure this?
    V Speirs
    Br J Cancer 87:687; author reply 688-9. 2002
  5. pmc Male breast carcinoma: increased awareness needed
    Jonathan White
    Department of Surgery, Leeds General Infi rmary, Great George Street, Leeds LS1 3EX, UK
    Breast Cancer Res 13:219. 2011
    ..The clinical management of male breast carcinoma is considered, in particular the potential role of aromatase inhibitors and fulvestrant and targeting pathways involving prolactin and androgen receptor...
  6. pmc British Cancer Research Meeting, 30 June-3 July 2002, Glasgow
    Alicia T Parkes
    Molecular Medicine Unit, University of Leeds, UK
    Breast Cancer Res 4:202-4. 2002
    ..The emphasis was clear: patient survival is the main priority and treatment of organ-specific cancer must inevitably be replaced by individualised tumour-specific therapy...
  7. ncbi request reprint Hormone receptors in defining breast cancer prognosis--time for a rethink?
    Valerie Speirs
    Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James s University Hospital, Beckett Street, Leeds LS9 7TK, UK
    Nat Clin Pract Oncol 4:204-5. 2007
  8. ncbi request reprint Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients
    V Speirs
    Department of Medicine, University of Hull, England, United Kingdom
    Cancer Res 59:5421-4. 1999
    ..These results lend further support to a role for ER-beta as a poor prognostic factor in breast cancer...
  9. ncbi request reprint Identification of wild-type and exon 5 deletion variants of estrogen receptor beta in normal human mammary gland
    V Speirs
    Medical Research Laboratory, University of Hull, United Kingdom
    J Clin Endocrinol Metab 85:1601-5. 2000
    ..07). In conclusion, our data would support a role for ERbeta in the normal human mammary gland, where we propose it may be the dominant receptor...
  10. ncbi request reprint Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?
    Valerie Speirs
    Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James s University Hospital, Leeds LS9 7TF, UK
    J Pathol 197:143-7. 2002
    ..In this review, the significance of ER beta in the human breast is reviewed with respect to recent literature and its possible implications are discussed...
  11. ncbi request reprint Pattern of expression of genes linked to epigenetic silencing in human breast cancer
    Kailas Munot
    Leeds Institute for Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK
    Hum Pathol 37:989-99. 2006
    ..This expression profile could be linked to epigenetic events, and if so, these pathways have potential as targets for therapeutic strategies based on reversal of epigenetic silencing...
  12. doi request reprint Expression of oestrogen receptor beta isoforms is regulated by transcriptional and post-transcriptional mechanisms
    Laura Smith
    Leeds Institute of Molecular Medicine, Leeds University, Leeds LS9 7TF, UK
    Biochem J 429:283-90. 2010
    ..In addition, we demonstrate how 17beta-oestradiol, a key driver of breast cancer development, affects the regulation of ERbeta expression at both transcriptional and translational levels...
  13. pmc Phosphorylation of estrogen receptor beta at serine 105 is associated with good prognosis in breast cancer
    Werbena Hamilton-Burke
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Am J Pathol 177:1079-86. 2010
    ..Presence of S105-ERbeta in breast cancer and association with improved survival, even in endocrine resistant breast tumors suggest S105-ERbeta might be a useful additional prognostic marker in this disease...
  14. ncbi request reprint Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro
    Jane L Limer
    Leeds Institute for Molecular Medicine, University of Leeds, St James s University Hospital, Leeds, United Kingdom
    Int J Cancer 119:515-21. 2006
    ....
  15. doi request reprint Differential regulation of oestrogen receptor β isoforms by 5' untranslated regions in cancer
    Laura Smith
    Leeds Institute of Molecular Medicine, Leeds University, Leeds, UK Department of Histopathology, St James s University Hospital, Leeds, UK
    J Cell Mol Med 14:2172-84. 2010
    ..Importantly, we also demonstrate that 5'UTRs allow the first reported mechanisms for differential regulation of the expression of the ERβ isoforms 1, 2 and 5, and thereby have critical influences on ERβ function...
  16. pmc Estrogen receptor {beta}1 expression is regulated by miR-92 in breast cancer
    Hakeemah Al-Nakhle
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom
    Cancer Res 70:4778-84. 2010
    ..Our results define a potentially important mechanism for downregulation of ERbeta1 expression in breast cancer...
  17. pmc MiR-26b is down-regulated in carcinoma-associated fibroblasts from ER-positive breast cancers leading to enhanced cell migration and invasion
    Eldo T Verghese
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK Department of Histopathology, St James s University Hospital, Leeds, UK
    J Pathol 231:388-99. 2013
    ..MiR-26b in breast CAFs is a potent regulator of cancer behaviour in oestrogen receptor-positive cancers, and we have identified key genes and molecular pathways that act downstream of miR-26b in CAFs...
  18. doi request reprint Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen
    Loaie Maraqa
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Clin Cancer Res 14:405-11. 2008
    ..The aim of this study was to determine the functional role of CEACAM6 in endocrine-resistant breast cancer and to retrospectively test whether it was predictive of resistance in a large cohort of breast cancers with long-term follow-up...
  19. ncbi request reprint The practicalities of using tissue slices as preclinical organotypic breast cancer models
    Deborah L Holliday
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    J Clin Pathol 66:253-5. 2013
    ..In summary, breast cancer tissue slices can be cultured in vitro as organotypic models. Nevertheless, although simple in concept, the delicacy of the model with regard to handling makes subsequent analytical processes challenging...
  20. ncbi request reprint Oestrogen receptor beta: what it means for patients with breast cancer
    Valerie Speirs
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    Lancet Oncol 5:174-81. 2004
    ..Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer...
  21. doi request reprint Epithelial-mesenchymal interactions in breast cancer: evidence for a role of nuclear localized β-catenin in carcinoma-associated fibroblasts
    Eldo T Verghese
    Department of Histopathology, Leeds Teaching Hospital NHS Trust, Leeds, UK
    Histopathology 59:609-18. 2011
    ..We have examined the prevalence and influence of nuclear β-catenin within the stromal fibroblasts of breast cancer...
  22. doi request reprint Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation
    Julie Richardson
    Leeds Institute of Molecular Medicine, University of Leeds, Wellcome Trust Brenner Building, St James s University Hospital, Leeds LS9 7TF, UK
    Breast Cancer Res Treat 127:639-48. 2011
    ..Microcephalin is an independent predictor of BCSS in invasive ductal breast cancer patients and may prove to be a useful biomarker for the identification of aggressive breast cancers...
  23. ncbi request reprint Reduced expression of oestrogen receptor beta in invasive breast cancer and its re-expression using DNA methyl transferase inhibitors in a cell line model
    George P Skliris
    Molecular Medicine Unit, University of Leeds, UK
    J Pathol 201:213-20. 2003
    ..These results suggest that loss of ER beta expression is one of the hallmarks of breast carcinogenesis and that it may be a reversible process involving methylation...
  24. doi request reprint Regulation of estrogen receptor β1 expression in breast cancer by epigenetic modification of the 5' regulatory region
    Hakeemah Al-Nakhle
    Leeds Institute of Cancer and Pathology, University of Leeds, Leeds LS9 7TF, UK
    Int J Oncol 43:2039-45. 2013
    ..A combination of de-methylating agents and histone deacetylase inhibitors fully restored ERβ1 expression which may offer a novel therapeutic angle for breast cancer management. ..
  25. doi request reprint Gene expression of ERbeta isoforms in laser microdissected human breast cancers: implications for gene expression analyses
    Michele Cummings
    Leeds Institute of Molecular Medicine, St James s University Hospital, Leeds, UK
    Cell Oncol 31:467-73. 2009
    ..This is largely due to discordant data between mRNA and protein studies as well as failure to take into account the biologically distinct ERbeta isoforms and their heterogeneous expression profile...
  26. ncbi request reprint Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients
    Abeer M Shaaban
    YCR and Liz Dawn Pathology and Translational Sciences Centre, Leeds Teaching Hospitals and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom
    Clin Cancer Res 14:5228-35. 2008
    ..Our aim was to elucidate the prognostic significance of ERbeta1, ERbeta2, and ERbeta5 by immunohistochemistry in a large cohort of breast carcinomas with long-term follow-up...
  27. ncbi request reprint PSMD9 expression predicts radiotherapy response in breast cancer
    Fiona E Langlands
    Leeds Institutes of Molecular Medicine, University of Leeds, Leeds, UK
    Mol Cancer 13:73. 2014
    ....
  28. doi request reprint External validation of the ImmunoRatio image analysis application for ERα determination in breast cancer
    Sreekumar Sundara Rajan
    Breast Research Group, Leeds Institute of Cancer and Pathology, St James University Hospital, Leeds, UK
    J Clin Pathol 67:72-5. 2014
    ..Our results support the use of ImmunoRatio software for analysing ERα immunohistochemistry in breast cancer tissues for the purposes of research. ..
  29. ncbi request reprint New perspectives into the biological and clinical relevance of oestrogen receptors in the human breast
    V Speirs
    Leeds Institute of Molecular Medicine, Wellcome Trust Brenner Building, St James s University Hospital, Leeds LS9 7TF, UK
    J Pathol 211:499-506. 2007
    ..Here we outline these changes and discuss what biological and clinical implications these could have in the mammary gland...
  30. ncbi request reprint Coexpression of estrogen receptor alpha and beta: poor prognostic factors in human breast cancer?
    V Speirs
    Department of Medicine, University of Hull, United Kingdom
    Cancer Res 59:525-8. 1999
    ..Thus, ER beta may be a useful prognostic factor in patients with breast cancer...
  31. doi request reprint The potential utility of geminin as a predictive biomarker in breast cancer
    Sreekumar Sundara Rajan
    Leeds Institute of Cancer Studies and Pathology, University of Leeds, Leeds, LS9 7TF, UK
    Breast Cancer Res Treat 143:91-8. 2014
    ..Selective expression of geminin during the proliferative phase of the cell cycle and its nuclear specificity increase its potential to be used as an alternative marker of proliferation in breast cancer patients. ..
  32. ncbi request reprint The value of archival tissue blocks in understanding breast cancer biology
    Thomas Dowsett
    Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK
    J Clin Pathol 67:272-5. 2014
    ..Important observations included the marked differences in pathological reporting, size of tumour and in ERα expression throughout the decades. ..
  33. doi request reprint Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts
    Samantha A Simpkins
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK
    J Pathol 227:490-8. 2012
    ..Our data confirm that loss of stromal Cav-1 in breast cancer predicts poor outcome. At a functional level, Cav-1-deficient CAFs are capable of significantly increasing the invasive capacity of breast cancer cells...
  34. ncbi request reprint Genetic events during the transformation of a tamoxifen-sensitive human breast cancer cell line into a drug-resistant clone
    R Achuthan
    Molecular Medicine Unit, University of Leeds, St. James's University Hospital, LS9 7TF, Leeds, UK
    Cancer Genet Cytogenet 130:166-72. 2001
    ..3, 22q13.1 approximately q13.2. These findings were supported by conventional cytogenetics and chromosome painting. The regions identified by CGH potentially harbor genes that could be important in the development of tamoxifen resistance...
  35. pmc Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling?
    G P Skliris
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Clinical Sciences Building, Leeds, LS9 7TF
    Br J Cancer 84:1095-8. 2001
    ..Here, we demonstrate for the first time, immunohistochemical detection of ERbeta in archival breast tumours...
  36. pmc Distinct expression patterns of ER alpha and ER beta in normal human mammary gland
    V Speirs
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Leeds LS9 7TF, UK
    J Clin Pathol 55:371-4. 2002
    ..The aim of this study was to compare the cellular distribution of ER alpha and ER beta in normal human mammary gland...
  37. ncbi request reprint Activity and gene expression of 17beta-hydroxysteroid dehydrogenase type I in primary cultures of epithelial and stromal cells derived from normal and tumourous human breast tissue: the role of IL-8
    V Speirs
    Department of Medicine, University of Hull, UK
    J Steroid Biochem Mol Biol 67:267-74. 1998
    ..This was reflected in 17-HSD type I activity. Thus, 17-HSD type I is constitutively expressed and active in normal and tumourous breast and can be regulated by IL-8...
  38. ncbi request reprint Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro
    D J Scott
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Int J Oncol 31:557-65. 2007
    ..Based on our results, it appears that increased co-activator expression, in concert with alterations in genes associated with controlling cell proliferation and survival contribute to TAMr in breast cancer...
  39. ncbi request reprint A multi-centre investigation towards reaching a consensus on the immunohistochemical detection of ERbeta in archival formalin-fixed paraffin embedded human breast tissue
    Pauline J Carder
    Department of Histopathology, St James s University Hospital, Leeds, UK
    Breast Cancer Res Treat 92:287-93. 2005
    ..Our results emphasise the need for further studies addressing the role of ERb to be based on a wider consensus on criteria for positivity. Ideally this should be based on calibration against clinical outcome...
  40. pmc Choosing the right cell line for breast cancer research
    Deborah L Holliday
    Leeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, UK
    Breast Cancer Res 13:215. 2011
    ....
  41. doi request reprint Loss of CSMD1 expression is associated with high tumour grade and poor survival in invasive ductal breast carcinoma
    Mohamed Kamal
    Leeds Institute of Molecular Medicine, University of Leeds, Wellcome Trust Brenner Building, Level 8, St James s University Hospital, Leeds LS9 7TF, UK
    Breast Cancer Res Treat 121:555-63. 2010
    ..The membrane expression pattern of CSMD1 suggests that it may be a receptor or co-receptor involved in the process of signal transduction...
  42. ncbi request reprint Intracellular flow cytometric analysis of primary cultured breast tumor cells
    Ruth L Loveday
    Department of Surgery, Medical Research Laboratory, Hull University, Cottingham Road, Hull, East Yorkshire HU6 7RX, UK
    Cancer Invest 20:340-7. 2002
    ..The methodology described will have many applications in studies requiring a highly pure population of epithelial breast cancer cells, as well as wide use in other cancers...
  43. doi request reprint A comparative biomarker study of 514 matched cases of male and female breast cancer reveals gender-specific biological differences
    Abeer M Shaaban
    St James s Institute of Oncology, St James s University Hospital, Leeds, UK
    Breast Cancer Res Treat 133:949-58. 2012
    ..With the incidence of male breast cancer increasing this provides impetus for further study...
  44. pmc Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours
    V Speirs
    Department of Medicine, University of Hull, UK
    Br J Cancer 80:898-903. 1999
    ....
  45. ncbi request reprint Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue
    G P Skliris
    Molecular Medicine Unit, University of Leeds, Leeds, UK
    J Pathol 197:155-62. 2002
    ..However, there is considerable variation between the specificity and application of these antibodies, highlighting the fact that careful optimization is required when selecting an antibody for use in a particular laboratory technique...
  46. ncbi request reprint Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging
    N Jassam
    Academic Unit of Pathology, University of Leeds, Leeds, LS9 7TF, UK
    Oncol Rep 14:17-21. 2005
    ..Its presence may be a favourable prognostic marker in this disease and could explain the protective effect of oestrogens against colon cancer development...
  47. doi request reprint The potential role of ER beta isoforms in the clinical management of breast cancer
    C A Green
    Pathology and Tumour Biology, Leeds Institute of Molecular Medicine, St James s University Hospital, University of Leeds, Leeds, UK
    Histopathology 53:374-80. 2008
    ..This review sets out to identify the present state of knowledge regarding the clinicopathological role of ER beta isoforms and discusses possible reasons for conflicting results arising from recent research findings...
  48. pmc Vascular endothelial growth factor in premenopausal women--indicator of the best time for breast cancer surgery?
    K Heer
    Academic Surgical Unit, University of Hull, Castle Hill Hospital, Cottingham, East Yorkshire, UK
    Br J Cancer 78:1203-7. 1998
    ..This fall in VEGF may be an effect of progesterone and should be the focus of future studies...
  49. ncbi request reprint Constitutive co-expression of estrogen and progesterone receptor mRNA in human meningiomas by RT-PCR and response of in vitro cell cultures to steroid hormones
    V Speirs
    Department of Medicine, University of Hull, UK
    Int J Cancer 72:714-9. 1997
    ..However, these receptors may not be functional in all tumours...
  50. pmc Short-term primary culture of epithelial cells derived from human breast tumours
    V Speirs
    Department of Medicine, University of Hull, UK
    Br J Cancer 78:1421-9. 1998
    ....
  51. pmc Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells
    V Speirs
    Department of Medicine, University of Hull, UK
    Br J Cancer 82:1312-6. 2000
    ..In conclusion, these results provide evidence for direct transcriptional activation of ERalpha by IL-6...
  52. pmc Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity
    L J Coleman
    Leeds Institute of Molecular Medicine, Leeds University, Leeds LS9 7TF, UK
    Br J Cancer 100:1393-9. 2009
    ..We conclude that eIF4E's influence on cancer survival is modulated substantially by 4E-BPs, and that combined pathway analyses can estimate functional eIF4E...
  53. pmc In vivo and in vitro expression of steroid-converting enzymes in human breast tumours: associations with interleukin-6
    V Speirs
    Department of Medicine, University of Hull, UK
    Br J Cancer 81:690-5. 1999
    ..In conclusion, we propose that these enzymes work in tandem with cytokines thereby providing sufficient quantities of bioactive oestrogen from less active precursors which stimulates tumour growth...
  54. ncbi request reprint Steroid hormone receptor expression in male breast cancer
    C E Murphy
    Molecular Medicine Unit, St James s University Hospital, University of Leeds, Clinical Sciences Building, Leeds LS9 7TF, UK
    Eur J Surg Oncol 32:44-7. 2006
    ..To investigate expression of the steroid hormone receptors estrogen receptor (ER)-alpha and -beta, progesterone receptor (PR) and androgen receptor (AR) in male breast cancer...
  55. ncbi request reprint Clinicians' guide to microarrays
    L Maraqa
    Pathology and Tumour Biology, Leeds Institute for Molecular Medicine, St James s University Hospital, Leeds LS9 7TF, UK
    Surg Oncol 15:205-10. 2006
    ..Here, we describe the different types of microarrays available and discuss their pros and cons from a clinical perspective, with respect to breast cancer...
  56. ncbi request reprint Cytokine expression in human anterior pituitary adenomas
    V L Green
    Department of Medicine, University of Hull, Liverpool, UK
    Clin Endocrinol (Oxf) 45:179-85. 1996
    ..Therefore profiles of cytokine expression were determined in different human anterior pituitary adenoma sub-types...
  57. ncbi request reprint Angiogenesis in breast cancer: how should we measure this? (Review)
    M J K Pollitt
    Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St James s University Hospital, Leeds LS9 7TF, UK
    Oncol Rep 13:931-6. 2005
    ..Here we review the pros and cons of current methods of assessing angiogenesis, both clinical and in the laboratory, and discuss with respect to breast cancer...
  58. ncbi request reprint The estrogen receptors alpha, beta, and beta cx
    Abeer M Shaaban
    Clin Cancer Res 11:8222; author reply 8222-3. 2005
  59. doi request reprint Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, United Kingdom
    J Clin Oncol 26:1059-65. 2008
    ....
  60. ncbi request reprint A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer
    Neil Johnson
    Northern Institute for Cancer Research, Paul O Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
    Breast Cancer Res Treat 111:55-63. 2008
    ..However, the antiestrogen resistant phenotype was likely to be due to changes in gene expression and protein degradation rather than in altered gene copy number...
  61. ncbi request reprint Correspondence re: S. A. W. Fuqua et al., Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res.,63: 2434-2439, 2003
    Valerie Speirs
    Cancer Res 63:9055. 2003
  62. ncbi request reprint Correspondence re: K. Heer et al., serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin. Cancer Res., 7: 3491-3494, 2001
    Claire E Murphy
    Clin Cancer Res 9:3514; author reply 3515. 2003
  63. ncbi request reprint Estrogen receptor beta--which one and where should we draw the line?
    Abeer M Shaaban
    Hum Pathol 37:498; author reply 499-500. 2006
  64. ncbi request reprint Promoter switch: a novel mechanism causing biallelic PEG1/MEST expression in invasive breast cancer
    Inge Søkilde Pedersen
    Department of Pathology, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland
    Hum Mol Genet 11:1449-53. 2002
    ....